COST-EFFECTIVENESS ANALYSIS OF VILDAGLIPTIN VS. GLIMEPIRIDE AS ADD-ON TO METFORMIN IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN GREECE

被引：1
作者：
Kousoulakou, H. [1 ]
Kalogeropoulou, M. [2 ]
Panitti, E. [2 ]
机构：
[1] Univ Peloponnese, Corinth, Greece
[2] Novartis Hellas, Metamorfosis, Greece
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2101
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB62
引用
收藏
页码：A608 / A608
页数：1
相关论文
共 50 条
  • [31] Vildagliptin versus insulin as add-on therapy to glimepiride in type 2 diabetes mellitus: results from a randomised controlled trial
    Strotmann, H. -J.
    Goetze, D.
    Koch, C.
    Forst, T.
    DIABETOLOGIA, 2014, 57 : S364 - S365
  • [32] COST-EFFECTIVENESS ANALYSIS OF METFORMIN COMBINED WITH SAXAGLIPTIN VS. METFORMIN COMBINED WITH SULFONYLUREAS IN TYPE 2 DIABETES PATIENTS IN ARGENTINA
    Elgart, J.
    Caporale, J.
    Gagliardino, J. J.
    Aiello, E. C.
    Waschbusch, M.
    Jotimliansky, L.
    VALUE IN HEALTH, 2010, 13 (03) : A61 - A61
  • [33] Assessment of empagliflozin add-on therapy to metformin and glimepiride in patients with inadequately controlled type-2 diabetes mellitus
    Jawed, Bilal
    Ahmed, Shadab
    Abbas, Syed Qamar
    Ahmed, Zeeshan
    Andleeb, Shomaiza
    Ahmad, Salman Ashfaq
    Asif, Muhammad
    Akhter, Erum
    Ahmed, Salman
    Hussain, Muhammad Waleed
    Iqbal, Adnan
    Ishaqui, Azfar Athar
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 35 (06) : 1733 - 1738
  • [34] Empaglilozin compared with glimepiride as add-on to metformin for 2 years in patients with type 2 diabetes
    Ridderstrale, M.
    Andersen, K. R.
    Zeller, C.
    Kim, G.
    Woerle, H. J.
    Broedl, U. C.
    DIABETOLOGIA, 2014, 57 : S7 - S8
  • [35] DAPAGLIFLOZIN: COST EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES IN ECUADOR
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Sanchez, Solis C.
    Acosta, W.
    Solorzano, J.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2016, 19 (03) : A202 - A202
  • [36] COST-EFFECTIVENESS OF FIXED-DOSE COMBINATION (FDC) OF VILDAGLIPTIN/METFORMIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 IN MEXICO
    Lemus, A.
    Jimenez Aranda, P.
    VALUE IN HEALTH, 2013, 16 (07) : A689 - A689
  • [37] COST-EFFECTIVENESS ANALYSIS OF USING HYPOGLYCEMIC AGENTS (LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN, GLIMEPIRIDE AND GLIBENCLAMIDE) WITH METFORMIN IN DIABETES IN COLOMBIA
    Romero, M.
    Marrugo, R.
    Sanchez, O.
    Lopez, S.
    Alvis, N.
    VALUE IN HEALTH, 2013, 16 (03) : A163 - A163
  • [38] ECONOMIC EVALUATION OF VILDAGLIPTIN AS ADD-ON THERAPY TO METFORMIN IN DIABETES MELLITUS TREATMENT IN CHINA
    Chen, W.
    Zhu, J.
    VALUE IN HEALTH, 2012, 15 (07) : A664 - A664
  • [39] Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China
    Gu, Shuyan
    Deng, Jing
    Shi, Lizheng
    Mu, Yiming
    Dong, Hengjin
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (10) : 808 - 820
  • [40] COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES IN THE NETHERLANDS
    van Haalen, H. G. M.
    Pompen, M.
    Bergenheim, K.
    McEwan, P.
    Townsend, R.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
12345